← boardnext 2026-08
IGC
IGC Pharma, LLCdistress 7/10 · high distress / dilution risk$0.270%today-43% from 52w high
Neurology 1
Lead: Alzheimer Disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+10%
Price & events
-10.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+3.5%
1W
-0.3%
1M
-20.8%
3M
-7.2%
6M
-32.7%
1Y
-42.7%
2Y
-85.7%
5Y
-83.9%
All
Overview
- Market Cap
- $26.94M
- Enterprise Value
- $26.87M
- Volume
- 12.82K
- 52 Week Range
- $0.25 – $0.47
- Total Shares
- 100.09M
- Float Shares
- 86.08M
- Short %
- 0.79%
- % Held by Insiders
- 13.38%
- % Held by Institutions
- 21.70%
- RVOL
- 0.03x
- Beta
- 0.46
Pipeline stages · 1 programs
IGC-AD1-Active
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 2 | IGC-AD1-Active | Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression | 164 | recruiting |
Catalyst news & presentations · 1
- 2026-03-30partnershipStrategic national media partnership with FMW Media Works LLC (New to The Street)SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-08Ascendiant CapitalBuy
- 2026-04-08Ascendiant CapitalBuy
- 2026-02-23Ascendiant CapitalBuy
- 2025-12-09Ascendiant CapitalBuy
- 2025-08-26Ascendiant CapitalBuy
- 2025-03-06Alliance Global PartnersBuy
Competitors — Alzheimer Disease
- LLYELI LILLY & Co$1094.4B · D3
- JNJJOHNSON & JOHNSON$617.4B · D0
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- ARWRARROWHEAD PHARMACEUTICALS, INC.$12.3B · D3
- LNTHLantheus Holdings, Inc.$6.6B · D0
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- ABOSAcumen Pharmaceuticals, Inc.$157M · D6
- INMBInmune Bio, Inc.$47M · D5
- NRSNNeuroSense Therapeutics Ltd.$22M · D5
Recent news
- 2026-07-19Price to earnings forward of IGC Pharma, Inc. – SWB:IGS1 - TradingView
- 2026-07-16IGC Pharma Q1 2026 Earnings: Narrower Loss Meets Improved Efficiency Amid Market Slump - EPS Surprise History - dars.gov.et
- 2026-07-14IGC Pharma (NYSE: IGC) maps $3B–$10B Alzheimer’s agitation market in new deck - Stock Titan
- 2026-07-14IGC Pharma furnishes updated investor presentation, details CALMA Phase 2 progress and interim data - TradingView
- 2026-07-14IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026 - Barchart.com
- 2026-07-14IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026 - Barchart.com
- 2026-07-13IGC Pharma Showcases AI Portfolio at AAIC 2026 - ACCESS Newswire
- 2026-07-10IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer’s Drug Development and Key 2026 Catalysts on The Street Podcast - Nonstop Local News
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.